Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alimera Sciences Inc (ALIM)

Alimera Sciences Inc (ALIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,869
  • Shares Outstanding, K 5,132
  • Annual Sales, $ 53,940 K
  • Annual Income, $ -10,440 K
  • 60-Month Beta 1.73
  • Price/Sales 0.70
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ALIM with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year 0.08
  • Growth Rate Est. (year over year) -212.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.05 +87.16%
on 12/31/20
7.75 -2.19%
on 01/19/21
+3.39 (+80.91%)
since 12/18/20
3-Month
3.82 +98.38%
on 11/03/20
7.75 -2.19%
on 01/19/21
+2.97 (+64.43%)
since 10/19/20
52-Week
2.86 +165.02%
on 03/19/20
8.49 -10.76%
on 02/27/20
+0.53 (+7.52%)
since 01/17/20

Most Recent Stories

More News
Alimera Sciences Announces Preliminary Top-line Results for Fourth Quarter and Full-Year 2020

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of...

ALIM : 7.58 (+14.85%)
Ocular Inflammation Treatment Market 2021, Global Research Analysis Report Growth at CAGR Value, Industry Share, Key Company Profiles, Type, Applications, Size, Trends and Forecast To 2027

The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.

AKRX : 0.0900 (-51.01%)
ALIM : 7.58 (+14.85%)
AGN : 193.02 (+0.02%)
NVS : 96.69 (+1.11%)
PFE : 36.73 (+0.08%)
VRX.TO : 30.80 (-3.33%)
Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President...

ALIM : 7.58 (+14.85%)
Worldwide Industry for Uveitis Treatment to 2025 - by Treatment Type, Disease Type, Cause, Distribution Channel and Region

, /PRNewswire/ -- The report has been added to offering.

ABBV : 112.18 (+1.50%)
ALIM : 7.58 (+14.85%)
ENZ : 3.20 (+5.26%)
NVS : 96.69 (+1.11%)
REGN : 533.89 (+3.08%)
Bristol Myers' (BMY) CNS Phase III Cancer Study on Opdivo Fails

Bristol Myers' (BMY) phase III study on Opdivo in newly diagnosed glioblastoma failed to meet goals.

ALKS : 22.85 (+2.15%)
BMY : 66.74 (+0.30%)
ALIM : 7.58 (+14.85%)
ARPO : 1.2700 (+5.83%)
Jazz (JAZZ) Initiates BLA Submission for Leukemia Candidate

Jazz (JAZZ) initiates the submission of a BLA to the FDA for the marketing approval of JZP-458 for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma.

JAZZ : 167.00 (-0.42%)
ALIM : 7.58 (+14.85%)
ARPO : 1.2700 (+5.83%)
ASLN : 2.05 (+6.77%)
ChemoCentryx (CCXI) Reports Positive Top-Line Rare Disease Data

ChemoCentryx (CCXI) and Vifor Fresenius Medical Care Renal Pharma report positive top-line data from the study evaluating avacopan for the treatment of C3 Glomerulopathy.

ALIM : 7.58 (+14.85%)
CCXI : 60.88 (-1.84%)
ARPO : 1.2700 (+5.83%)
ASLN : 2.05 (+6.77%)
Veracyte (VCYT) in Focus: Stock Moves 7% Higher

Veracyte (VCYT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

ALIM : 7.58 (+14.85%)
VCYT : 53.40 (+5.14%)
Novo Nordisk (NVO) Files for Semaglutide Label Expansion in EU

Novo Nordisk (NVO) files application in Europe for the label expansion of subcutaneous Ozempic (semaglutide) 2.4 mg.

NVO : 73.02 (+1.37%)
ALIM : 7.58 (+14.85%)
ARPO : 1.2700 (+5.83%)
ASLN : 2.05 (+6.77%)
Berkeley Lights (BLI) in Focus: Stock Moves 6.3% Higher

Berkeley Lights (BLI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

ALIM : 7.58 (+14.85%)
BLI : 80.83 (-3.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes...

See More

Key Turning Points

3rd Resistance Point 8.98
2nd Resistance Point 8.36
1st Resistance Point 7.97
Last Price 7.58
1st Support Level 6.97
2nd Support Level 6.35
3rd Support Level 5.96

See More

52-Week High 8.49
Last Price 7.58
Fibonacci 61.8% 6.34
Fibonacci 50% 5.68
Fibonacci 38.2% 5.01
52-Week Low 2.86

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar